Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528465 | 0.83 | DHFR (0.42) | TLK2MDM2CHEK1GSK3BRET | |
| SCHEMBL8528517 | 0.82 | TLK2 (0.42) | TLK2MDM2LRRK2MEN1KMT2A | |
| SCHEMBL8530158 | 0.82 | RET (0.45) | MEN1KMT2ACHEK1GSK3BRET | |
| SCHEMBL8587052 | 0.80 | NTRK1 (0.60) | TLK2LRRK2MEN1KMT2ACHEK1 | |
| SCHEMBL8587050 | 0.80 | NTRK1 (0.60) | TLK2LRRK2MEN1KMT2ACHEK1 | |
| SCHEMBL8529758 | 0.80 | PDPK1 (0.52) | LRRK2MEN1KMT2ACHEK1RET | |
| SCHEMBL8301615 | 0.80 | TLK2 (0.58) | TLK2MEN1KMT2A | |
| SCHEMBL8292593 | 0.78 | PDPK1 (0.58) | TLK2MEN1KMT2ACHEK1GSK3B | |
| SCHEMBL7131127 | 0.78 | NTRK1 (0.47) | LRRK2MEN1KMT2ACHEK1GSK3B | |
| SCHEMBL8508649 | 0.78 | RPS6KA3 (0.54) | MEN1KMT2ACHEK1GSK3BRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5840745-A | INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY | PHARMACIA S. P. A. (IT) | 1998-11-24 | — | — | US | claimed |
| EP-0752985-A1 | HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-01-15 | — | — | EP | claimed |
| WO-1996022976-A1 | HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1996-08-01 | — | — | WO | claimed |
| US-5840745-A | INHIBITING CELL PROLIFERATION, TUMOR GROWTH, METASTASIS, DEVELOPMENT OF ATHEROMATOUS PLAQUE AND RESTENOSIS, CONTROLLING ANGIOGENESIS, TREATING DIABETES, ENHANCING CANCER THERAPY | PHARMACIA S. P. A. (IT) | 1998-11-24 | — | — | US | disclosed |
| EP-0752985-A1 | HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.p.A. (IT) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996022976-A1 | HYDROSOLUBLE 3-ARYLIDENE-2-OXINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1996-08-01 | — | — | WO | disclosed |